Monday, March 15, 2021

Flu Vaccine Reduces COVID-19 Infection and Severity

Main article image
 

In this Issue

•  IVIG/Albumin Supply Index
•  Open Market Pricing
•  New Products from FFF
•  Current Medicare
IVIG / SCIG Rates
•  Resources
•  Subscribe to IG Living and BioSupply Trends Quarterly
 

A recent study shows the odds of testing positive for COVID-19 was reduced in patients who received an influenza (flu) vaccine compared to those who did not by 24 percent. It also found those who tested positive for COVID-19 were less likely to require hospitalization or mechanical ventilation and had a shorter hospital length and stay. read more ]

Only One COVID-19 Shot Effective in Recovered Patients

Six recent studies suggest people who have already been infected with the COVID-19 virus may need only one dose of the protective vaccine since the first vaccine provides such a huge boost, which means the second vaccine makes little difference. However, the federal government has not changed its recommendation for a second dose. read more ]

COVID-19 Vaccine Response to Be Tested in Children

The University of Oxford has launched a study to assess the safety and immune response of its COVID-19 vaccine in children between ages 6 years and 17 years. Trials are set to begin later this month at Oxford University and its partner sites in London, Southampton and Bristol. read more ]

Industry News

 
Industry News Image
 

From Moderna

The U.S. Food and Drug Administration says Moderna can put up to 40 percent more coronavirus vaccine into each of its vials, providing a simple and potentially rapid way to bolster strained supplies.  [ read more ]

From Johnson & Johnson

An emergency use authorization has been issued by the U.S. Food and Drug Administration for Johnson & Johnson's COVID-19 vaccine for individuals 18 years of age and older. This third COVID-19 vaccine is an adenovector vaccine that requires only one dose and can be stored at refrigerator temperatures for up to three months. read more ]

From Adaptive Biotechnologies Corp.

An emergency use authorization has been given by the U.S. Food and Drug Administration for T-Detect™ COVID to confirm recent or prior COVID-19 infection. read more ]

From Regeneron Pharmaceuticals

The U.S. Food and Drug Administration has approved Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn), a mixture of three monoclonal antibodies, as the first treatment for Zaire ebolavirus (Ebola virus) infection in adult and pediatric patients. read more ]

IVIG & Albumin Supply Index

IVIG and Albumin Days On Hand
     
 
 
 
     

What's New at FFF

EVKEEZA  (REGENERON PHARMACEUTICALS)

EVKEEZA (evinacumab-dgnab) injection is an ANGPTL3 (angiopoietin-like 3) inhibitor indicated as an adjunct to other low-density lipoprotein-cholesterol lowering therapies for the treatment of adult and pediatric patients aged 12 years and older with homozygous familial hypercholesterolemia. It is supplied as one 345 mg/2.3 mL or 1,200 mg/8 mL single-dose vial per carton.

For more information about EVKEEZA, log in to biosupply.fffenterprises.com

DOCETAXEL (HOSPIRA INC.)

DOCETAXEL injection is indicated for treatment of patients with 1) locally advanced or metastatic breast cancer after failure of prior chemotherapy, and in combination with doxorubicin and cyclophosphamide for the adjuvant treatment of patients with operable node-positive breast cancer; 2) locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy, and in combination with cisplatin for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition; 3) metastatic castration-resistant prostate cancer in combination with prednisone; 4) advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease; and 5) locally advanced squamous cell carcinoma of the head and neck in combination with cisplatin and fluorouracil. It is supplied in 20 mg/1 mL single-dose vials, and 80 mg/4 mL and 160 mg/8 mL multiple-dose vials as a sterile, pyrogen-free, non-aqueous pale-yellow to brownish yellow solution.

For more information about DOCETAXEL, log in to biosupply.fffenterprises.com

ZILRETTA (FLEXION THERAPEUTICS)

ZILRETTA (triamcinolone acetonide injectable suspension) is an extended-release synthetic corticosteroid indicated as an intra-articular injection for the management of osteoarthritis pain of the knee. It is supplied as 1) a 5 mL single-dose vial to deliver 32 mg of triamcinolone acetonide supplied as a sterile white to off-white powder in a clear vial, and 2) a 5 mL single-dose vial supplied as a sterile, clear liquid solution of 0.9% w/w sodium chloride (normal saline) containing 0.5% w/w sodium carboxymethylcellulose, and 0.1% w/w polysorbate-80 in a glass vial.

For more information about ZILRETTA, log in to biosupply.fffenterprises.com

HIZENTRA PRE-FILLED SYRINGES (CSL BEHRING)

HIZENTRA (immune globulin subcutaneous [human] 20% liquid) PRE-FILLED SYRINGES for primary immunodeficiency patients are ready to use, eliminating the need to transfer the drug from the vial to a syringe. The syringes come in 5 mL and 10 mL (fully assembled) and 20 mL (requiring the plunger rod to be screwed onto the syringe stopper prior to use).

For more information about HIZENTRA PRE-FILLED SYRINGES, log in to biosupply.fffenterprises.com

These products can be ordered from FFF Enterprise's BioSupply Online Ordering System or by calling
Wow! Customer Care at (800) 843-7477.

Current Medicare IVIG / SCIG Rates

Rates per gram are effective Jan. 1, 2021, through March 30, 2021.

 
Product J Codes ASP + 6%
(before sequester)
ASP + 4.3%*
(after sequester)
IVIG
ASCENIV 90283 / J1599 ** **
BIVIGAM J1556 $140.98 $138.72
FLEBOGAMMA J1572 $73.72 $72.54
GAMMAGARD SD J1566 $133.94 $131.80
GAMMAPLEX J1557 $99.62 $98.02
OCTAGAM J1568 $83.26 $81.93
PANZYGA 90283 / J1599 ** **
PRIVIGEN J1459 $84.85 $83.49
SCIG
CUTAQUIG 90284 / J3590 ** **
CUVITRU J1555 $139.44 $137.20
HIZENTRA J1559 $110.94 $109.16
HYQVIA J1575 $143.36 $141.06
XEMBIFY J1558 $146.87 $144.51
IVIG / SCIG
GAMMAGARD LIQUID J1569 $87.25 $85.85
GAMMAKED J1561 $87.35 $85.95
GAMUNEX-C J1561 $87.35 $85.95

* Reflects 2% sequestration reduction applied to 80% Medicare payment portion as required under Budget Control Act of 2011.
** ASP-based Medicare payment rate not yet available; payment rate assigned by your Medicare Administrative Contractor.

 

Resources

FFF customers may order the following complementary resources to help you with your practice:

•  IG Immune Globulin (Human)
•  Hyperimmune Globulins
•  Anti-Inhibitor, Factor VIIa & IX
•  Factor VIII & von Willebrand Factor
•  Seasonal Influenza Vaccine

Subscribe to IG Living

IG Living is the only magazine for the immune globulin (IG) community for patients who suffer from chronic illness and their caregivers.

Subscribe to BioSupply
Trends Quarterly

BioSupply Trends Quarterly magazine is the definitive source for industry trends, news and information for the biopharmaceuticals marketplace.

Home | About | Advertise | Subscribe | Contact – © FFF Enterprises, Inc.